Management of hepatocellular carcinoma from diagnosis in routine clinical practice

To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire av...

Full description

Saved in:
Bibliographic Details
Published in:Hepatic oncology 2022-12, Vol.9 (4), p.HEP45-HEP45
Main Authors: Lokhandwala, Tasneem, Aly, Abdalla, Farrelly, Eileen, Willey, Joanne P, Lamerato, Lois E, Healey, Marcus, Coutinho, Anna D, Seal, Brian S
Format: Article
Language:English
Subjects:
Child-Pugh class
hepatocellular carcinoma
liver resection/excision
liver transplantation
locoregional therapies
overall survival
radiofrequency ablation
Short Communication
transarterial chemoembolization
transarterial radioembolization
treatment journey
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c504t-c59075d6f6435fcf058bd84cc45099eae590ccf17d1a5816c3098caa480519a23
cites cdi_FETCH-LOGICAL-c504t-c59075d6f6435fcf058bd84cc45099eae590ccf17d1a5816c3098caa480519a23
container_end_page HEP45
container_issue 4
container_start_page HEP45
container_title Hepatic oncology
container_volume 9
creator Lokhandwala, Tasneem
Aly, Abdalla
Farrelly, Eileen
Willey, Joanne P
Lamerato, Lois E
Healey, Marcus
Coutinho, Anna D
Seal, Brian S
description To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient. Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72–82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.
doi_str_mv 10.2217/hep-2021-0011
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a2b0419ef36041ee82d2d7a227927037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a2b0419ef36041ee82d2d7a227927037</doaj_id><sourcerecordid>2794692867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-c59075d6f6435fcf058bd84cc45099eae590ccf17d1a5816c3098caa480519a23</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhSMEolXpki3Kkk3K2HF-vEKoAlqpiAWwtuZOxreuEvtiJ0h9G56FJ8Mh5You2Phvjr8zmlMULwVcSCm6N7d8qCRIUQEI8aQ4laCaCnQtnh7Psj4pzlO6gyyRTQtKPy9O6g5AKwmnxZdP6HHPE_u5DLbMQJwD8TguI8aSMJLzYcJfP20MUzk43PuQXCqdL2NYZue5pNF5RziWh4g0O-IXxTOLY-Lzh_2s-Pbh_dfLq-rm88fry3c3FTWg5rxq6Jqhta2qG0sWmn439IpINaA1I-c6kRXdILDpRUs16J4QVQ-N0Cjrs-J64w4B78whugnjvQnozJ-HEPcGY25oZINyB0potnWegGDu5SCHDqXstOyg7jLr7cY6LLuJB8rziDg-gj6ueHdr9uGHEQCtkq3IhNcPhBi-L5xmM7m0ThI9hyWZbKVaLft2Nas2KcWQUmR79BFg1mBNzsGswZo12Kx_9W9zR_XfGLNAbwK7zEvkRI49sdlu-YfLKfJ_4L8BuVOzMg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2794692867</pqid></control><display><type>article</type><title>Management of hepatocellular carcinoma from diagnosis in routine clinical practice</title><source>PubMed Central</source><creator>Lokhandwala, Tasneem ; Aly, Abdalla ; Farrelly, Eileen ; Willey, Joanne P ; Lamerato, Lois E ; Healey, Marcus ; Coutinho, Anna D ; Seal, Brian S</creator><creatorcontrib>Lokhandwala, Tasneem ; Aly, Abdalla ; Farrelly, Eileen ; Willey, Joanne P ; Lamerato, Lois E ; Healey, Marcus ; Coutinho, Anna D ; Seal, Brian S</creatorcontrib><description>To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient. Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72–82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.</description><identifier>ISSN: 2045-0923</identifier><identifier>EISSN: 2045-0931</identifier><identifier>DOI: 10.2217/hep-2021-0011</identifier><identifier>PMID: 37009420</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Child-Pugh class ; hepatocellular carcinoma ; liver resection/excision ; liver transplantation ; locoregional therapies ; overall survival ; radiofrequency ablation ; Short Communication ; transarterial chemoembolization ; transarterial radioembolization ; treatment journey</subject><ispartof>Hepatic oncology, 2022-12, Vol.9 (4), p.HEP45-HEP45</ispartof><rights>2023 AstraZeneca PLC</rights><rights>2023 AstraZeneca PLC.</rights><rights>2023 AstraZeneca PLC 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-c59075d6f6435fcf058bd84cc45099eae590ccf17d1a5816c3098caa480519a23</citedby><cites>FETCH-LOGICAL-c504t-c59075d6f6435fcf058bd84cc45099eae590ccf17d1a5816c3098caa480519a23</cites><orcidid>0000-0002-1983-9557</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064261/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064261/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37009420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lokhandwala, Tasneem</creatorcontrib><creatorcontrib>Aly, Abdalla</creatorcontrib><creatorcontrib>Farrelly, Eileen</creatorcontrib><creatorcontrib>Willey, Joanne P</creatorcontrib><creatorcontrib>Lamerato, Lois E</creatorcontrib><creatorcontrib>Healey, Marcus</creatorcontrib><creatorcontrib>Coutinho, Anna D</creatorcontrib><creatorcontrib>Seal, Brian S</creatorcontrib><title>Management of hepatocellular carcinoma from diagnosis in routine clinical practice</title><title>Hepatic oncology</title><addtitle>Hepat Oncol</addtitle><description>To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient. Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72–82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.</description><subject>Child-Pugh class</subject><subject>hepatocellular carcinoma</subject><subject>liver resection/excision</subject><subject>liver transplantation</subject><subject>locoregional therapies</subject><subject>overall survival</subject><subject>radiofrequency ablation</subject><subject>Short Communication</subject><subject>transarterial chemoembolization</subject><subject>transarterial radioembolization</subject><subject>treatment journey</subject><issn>2045-0923</issn><issn>2045-0931</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kc1u1TAQhSMEolXpki3Kkk3K2HF-vEKoAlqpiAWwtuZOxreuEvtiJ0h9G56FJ8Mh5You2Phvjr8zmlMULwVcSCm6N7d8qCRIUQEI8aQ4laCaCnQtnh7Psj4pzlO6gyyRTQtKPy9O6g5AKwmnxZdP6HHPE_u5DLbMQJwD8TguI8aSMJLzYcJfP20MUzk43PuQXCqdL2NYZue5pNF5RziWh4g0O-IXxTOLY-Lzh_2s-Pbh_dfLq-rm88fry3c3FTWg5rxq6Jqhta2qG0sWmn439IpINaA1I-c6kRXdILDpRUs16J4QVQ-N0Cjrs-J64w4B78whugnjvQnozJ-HEPcGY25oZINyB0potnWegGDu5SCHDqXstOyg7jLr7cY6LLuJB8rziDg-gj6ueHdr9uGHEQCtkq3IhNcPhBi-L5xmM7m0ThI9hyWZbKVaLft2Nas2KcWQUmR79BFg1mBNzsGswZo12Kx_9W9zR_XfGLNAbwK7zEvkRI49sdlu-YfLKfJ_4L8BuVOzMg</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Lokhandwala, Tasneem</creator><creator>Aly, Abdalla</creator><creator>Farrelly, Eileen</creator><creator>Willey, Joanne P</creator><creator>Lamerato, Lois E</creator><creator>Healey, Marcus</creator><creator>Coutinho, Anna D</creator><creator>Seal, Brian S</creator><general>Future Medicine Ltd</general><general>Taylor &amp; Francis</general><scope>FUMOA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1983-9557</orcidid></search><sort><creationdate>202212</creationdate><title>Management of hepatocellular carcinoma from diagnosis in routine clinical practice</title><author>Lokhandwala, Tasneem ; Aly, Abdalla ; Farrelly, Eileen ; Willey, Joanne P ; Lamerato, Lois E ; Healey, Marcus ; Coutinho, Anna D ; Seal, Brian S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-c59075d6f6435fcf058bd84cc45099eae590ccf17d1a5816c3098caa480519a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Child-Pugh class</topic><topic>hepatocellular carcinoma</topic><topic>liver resection/excision</topic><topic>liver transplantation</topic><topic>locoregional therapies</topic><topic>overall survival</topic><topic>radiofrequency ablation</topic><topic>Short Communication</topic><topic>transarterial chemoembolization</topic><topic>transarterial radioembolization</topic><topic>treatment journey</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lokhandwala, Tasneem</creatorcontrib><creatorcontrib>Aly, Abdalla</creatorcontrib><creatorcontrib>Farrelly, Eileen</creatorcontrib><creatorcontrib>Willey, Joanne P</creatorcontrib><creatorcontrib>Lamerato, Lois E</creatorcontrib><creatorcontrib>Healey, Marcus</creatorcontrib><creatorcontrib>Coutinho, Anna D</creatorcontrib><creatorcontrib>Seal, Brian S</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Hepatic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lokhandwala, Tasneem</au><au>Aly, Abdalla</au><au>Farrelly, Eileen</au><au>Willey, Joanne P</au><au>Lamerato, Lois E</au><au>Healey, Marcus</au><au>Coutinho, Anna D</au><au>Seal, Brian S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of hepatocellular carcinoma from diagnosis in routine clinical practice</atitle><jtitle>Hepatic oncology</jtitle><addtitle>Hepat Oncol</addtitle><date>2022-12</date><risdate>2022</risdate><volume>9</volume><issue>4</issue><spage>HEP45</spage><epage>HEP45</epage><pages>HEP45-HEP45</pages><issn>2045-0923</issn><eissn>2045-0931</eissn><abstract>To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient. Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72–82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>37009420</pmid><doi>10.2217/hep-2021-0011</doi><orcidid>https://orcid.org/0000-0002-1983-9557</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-0923
ispartof Hepatic oncology, 2022-12, Vol.9 (4), p.HEP45-HEP45
issn 2045-0923
2045-0931
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a2b0419ef36041ee82d2d7a227927037
source PubMed Central
subjects Child-Pugh class
hepatocellular carcinoma
liver resection/excision
liver transplantation
locoregional therapies
overall survival
radiofrequency ablation
Short Communication
transarterial chemoembolization
transarterial radioembolization
treatment journey
title Management of hepatocellular carcinoma from diagnosis in routine clinical practice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20hepatocellular%20carcinoma%C2%A0from%20diagnosis%20in%20routine%20clinical%20practice&rft.jtitle=Hepatic%20oncology&rft.au=Lokhandwala,%20Tasneem&rft.date=2022-12&rft.volume=9&rft.issue=4&rft.spage=HEP45&rft.epage=HEP45&rft.pages=HEP45-HEP45&rft.issn=2045-0923&rft.eissn=2045-0931&rft_id=info:doi/10.2217/hep-2021-0011&rft_dat=%3Cproquest_doaj_%3E2794692867%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c504t-c59075d6f6435fcf058bd84cc45099eae590ccf17d1a5816c3098caa480519a23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2794692867&rft_id=info:pmid/37009420&rfr_iscdi=true